Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

VantAI. (4/20/22). "Press Release: VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders". new York, NY & Ingelheim.

Organisations Organisation VantAI (US)
  Group Roivant (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product AI-based drug discovery / AI-based drug development
  Product 2 protein degradation drug
Index term Index term Boehringer–Roivant: AI-based drug discovery, 202204– collab research €na with VantAI using AI/ML to identify protein degraders
Person Person Carpenter, Zachary (Zach) (Roivant 202402 CEO + Co-Founder of VantAI)

VantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets

VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally “undruggable” targets.

The collaboration will initially focus on one degrader program combined with multiple proprietary E3 ligase platforms. The two organizations and their scientists will leverage VantAI's geometric deep learning platform to computationally streamline the design of new molecules optimized for each E3 platform, leveraging unique target-E3 interface contacts to create innovative routes for important drug parameters such as potency and selectivity.

"We're extremely excited to partner with Boehringer Ingelheim in the induced proximity space, particularly on ‘undruggable’ disease targets, where new approaches are needed to overcome long-standing hurdles” said Dr. Zachary Carpenter, Founder and CEO of VantAI. “BI’s deep early discovery experience and VantAI’s unique geometric deep learning technology are well poised in combination to unlock novel solutions with significant advantages for patients”

Boehringer Ingelheim has provided VantAI with an undisclosed upfront consideration along with additional preclinical, clinical, and commercial milestones. In addition, Boehringer Ingelheim has exclusive commercial licenses to the degraders that are developed for the initial target under this agreement and will be responsible for global development and commercialization.

About VantAI

VantAI leverages the cell's most powerful systems through rationally-designed small molecule proximity inducers - building on nature's blueprint using Deep Learning. These ML models make VantAI uniquely suited to power a best-in-class solution for induced proximity, where the nuance of protein-protein interactions and the ability to understand and model large complex biological interactomes, such as protein degradation, has outsized influence on drug success. Our evolutionary scoring learns from naturally occurring interfaces, allowing generative models to design smaller more “glue-like” molecules that form highly cooperative ternary complexes. VantAI has collaborated with numerous leading biopharma partners to launch new development programs with exciting properties enabled through its unique ‘Protein-Contact-First’ approach—at a fraction of the time and cost of traditional methods. VantAI is a wholly-owned subsidiary of Roivant Sciences (Nasdaq: ROIV). For more information, please visit

Record changed: 2024-03-27


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Roivant (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top